 |
|
|
| |
Resmetirom effects on NASH with liver fibrosis in
patients with NASH genetic risk alleles
|
| |
| |
AASLD 2024 Nov 15-19
Naga P. Chalasani, MD, FAASLD1; Dominic Labriola2; Rebecca Taub, MD2; Quentin M. Anstee, MBBS, PhD, FRCP3
1Indiana University Medical Center, Indianapolis, IN; 2Madrigal Pharmaceuticals, Conshohocken, PA; 3Newcastle University, Newcastle, UK
|
| |
|
|
|
|
|
